Clinical effects of azasetoron / dexamethasone combination-therapy on the prevention of nausea and vomiting caused by chemotherapy treatment for colon cancer patients - Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy -

Clinical effects of azasetoron / dexamethasone combination-therapy on the prevention of nausea and vomiting caused by chemotherapy treatment for colon cancer patients - Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy - - Comparative cross-over trial between azasetoron single-therapy and azasetoron/dexamethasone combination-therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000406

Enrollment

100

Registered

2006-04-17

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Interventions

drip-infusion of azasetoron (10mg/body) before the administration of anti-cancer agents (day1) drip-infusion of azasetoron (10mg/body) and dexamethason (8mg/body) before the administration of anti-can

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Colon cancer patients to be administered with chemotherapeutic agents such as Irinotecan, Oxaliplatin, Levofolinate or 5-FU (underlying disease: colon cancer) Patients who have the abilities to agree with this study by themselves, or whose acceptance to this study can be obtained from their proxies in writing

Exclusion criteria

Exclusion criteria: Patients to receive surgical treatment or irradiation treatment during the term of this study Patients who develop complications of severe cardiovascular disease, hemodyscrasia, renal disease or hepatic disease. Pregnant or lactating women Patients with a history of hypersensitivity to any of the drugs used in this study.

Design outcomes

Primary

Measure	Time frame
inhibition rate of vomiting events	—

Secondary

Measure	Time frame
vomiting frequency, score of nausea, patient's feelings (anti-emesis, appetite)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026